EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO
- EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints GlobeNewswire
- Watertown biotech shares surge nearly 200% on new drug data – Boston Business Journal The Business Journals
- EyePoint Pharmaceuticals’ stock soars 200% after company announces positive data for macular degeneration treatment MarketWatch
- Why Is EyePoint Pharmaceuticals (EYPT) Stock Up 187% Today? InvestorPlace
- EyePoint’s macular degeneration drug shows promise The Boston Globe
- View Full Coverage on Google News
Read More: EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO